主要终点-话题@MedSci

#主要终点#

97篇内容 | 2440人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1996917, encodeId=8eb3199691e86, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=辉瑞疫苗Prevenar13用于老年患者研究达主要终点, objectType=article, longId=31343, objectId=1b11313436b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b11313436b, replyNumber=0, likeNumber=71, createdTime=2015-02-07, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b11313436b, moduleTitle=辉瑞疫苗Prevenar13用于老年患者研究达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b11313436b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996927, encodeId=faf3199692ecb, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=进仿制版3期临床达到主要终点，阿达木单抗霸主地位受到威胁？, objectType=article, longId=41284, objectId=eb594128469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb594128469, replyNumber=0, likeNumber=74, createdTime=2015-03-11, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb594128469, moduleTitle=进仿制版3期临床达到主要终点，阿达木单抗霸主地位受到威胁？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb594128469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996926, encodeId=9548199692633, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=MSD骨质疏松症药物Odanacatib达3期试验主要终点, objectType=article, longId=40667, objectId=895d4066e16, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=895d4066e16, replyNumber=0, likeNumber=0, createdTime=2015-08-11, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=895d4066e16, moduleTitle=MSD骨质疏松症药物Odanacatib达3期试验主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=895d4066e16)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996923, encodeId=bafb199692381, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=辉瑞CDK4/6抑制剂palbociclib II期达主要终点, objectType=article, longId=33003, objectId=65bc330037a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65bc330037a, replyNumber=0, likeNumber=81, createdTime=2014-09-22, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65bc330037a, moduleTitle=辉瑞CDK4/6抑制剂palbociclib II期达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65bc330037a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996925, encodeId=c9f019969251b, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=GSK单抗药Arzerra III期CLL研究未达主要终点, objectType=article, longId=37293, objectId=aa053e2935e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa053e2935e, replyNumber=0, likeNumber=64, createdTime=2014-10-23, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa053e2935e, moduleTitle=GSK单抗药Arzerra III期CLL研究未达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa053e2935e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996924, encodeId=1acf199692425, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=阿斯利康2种治疗自身免疫性疾病的单抗药物II期研究均达主要终点, objectType=article, longId=34818, objectId=075d3481802, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=075d3481802, replyNumber=0, likeNumber=70, createdTime=2014-07-02, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=075d3481802, moduleTitle=阿斯利康2种治疗自身免疫性疾病的单抗药物II期研究均达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=075d3481802)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996912, encodeId=b57019969128d, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=安斯泰来前列腺癌新药Xtandi III期PREVAIL达主要终点, objectType=article, longId=25824, objectId=c92d2582476, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c92d2582476, replyNumber=0, likeNumber=73, createdTime=2014-01-19, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c92d2582476, moduleTitle=安斯泰来前列腺癌新药Xtandi III期PREVAIL达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c92d2582476)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996915, encodeId=28e71996915f3, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=辉瑞戒烟药varenicline新研究达主要终点, objectType=article, longId=29874, objectId=8ed5298e4cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ed5298e4cb, replyNumber=0, likeNumber=86, createdTime=2014-10-11, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ed5298e4cb, moduleTitle=辉瑞戒烟药varenicline新研究达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ed5298e4cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996910, encodeId=623019969105c, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=辉瑞潜在重磅药物tofacitinib 2个III期研究达主要终点, objectType=article, longId=25277, objectId=4107252e7fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4107252e7fd, replyNumber=0, likeNumber=79, createdTime=2014-02-18, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4107252e7fd, moduleTitle=辉瑞潜在重磅药物tofacitinib 2个III期研究达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4107252e7fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996911, encodeId=1fad1996911d7, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=ECC 2013辩论场：PFS是有效的主要终点吗？, objectType=article, longId=25642, objectId=34db25642d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34db25642d9, replyNumber=0, likeNumber=66, createdTime=2013-11-20, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34db25642d9, moduleTitle=ECC 2013辩论场：PFS是有效的主要终点吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34db25642d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996908, encodeId=3b90199690849, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Isis制药反义药物Isis-CRP Rx II期RA研究未达主要终点, objectType=article, longId=22739, objectId=c50222e39db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c50222e39db, replyNumber=0, likeNumber=76, createdTime=2013-08-30, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c50222e39db, moduleTitle=Isis制药反义药物Isis-CRP Rx II期RA研究未达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c50222e39db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996916, encodeId=8af31996916c5, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=诺华抗癌药LDE225关键性BOLT研究达主要终点, objectType=article, longId=30912, objectId=3e72309122a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e72309122a, replyNumber=0, likeNumber=55, createdTime=2014-03-23, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e72309122a, moduleTitle=诺华抗癌药LDE225关键性BOLT研究达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e72309122a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996907, encodeId=46eb199690e77, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Pacira制药Exparel III期肋间神经阻滞试验未达主要终点, objectType=article, longId=22664, objectId=6d64226640b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d64226640b, replyNumber=0, likeNumber=78, createdTime=2014-02-26, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d64226640b, moduleTitle=Pacira制药Exparel III期肋间神经阻滞试验未达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d64226640b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996913, encodeId=634119969136f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=GSK冠心病药物darapladibIII期研究未达主要终点, objectType=article, longId=26582, objectId=49d2265824c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49d2265824c, replyNumber=0, likeNumber=67, createdTime=2014-09-19, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49d2265824c, moduleTitle=GSK冠心病药物darapladibIII期研究未达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49d2265824c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996914, encodeId=98d8199691474, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=赛诺菲新胰岛素U300 4个III期研究达主要终点, objectType=article, longId=27571, objectId=38942e571a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38942e571a4, replyNumber=0, likeNumber=70, createdTime=2014-06-19, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38942e571a4, moduleTitle=赛诺菲新胰岛素U300 4个III期研究达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38942e571a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996909, encodeId=6a9f19969091b, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=拜耳Eylea 2个III期糖尿病性黄斑水肿试验均达主要终点, objectType=article, longId=22742, objectId=237922e4273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=237922e4273, replyNumber=0, likeNumber=71, createdTime=2014-07-23, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=237922e4273, moduleTitle=拜耳Eylea 2个III期糖尿病性黄斑水肿试验均达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=237922e4273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996906, encodeId=5b2a199690629, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=骨关节炎镇痛药物ARRY-797的临床概念验证达到主要终点, objectType=article, longId=9809, objectId=58ca9809c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58ca9809c5, replyNumber=0, likeNumber=73, createdTime=2013-05-10, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58ca9809c5, moduleTitle=骨关节炎镇痛药物ARRY-797的临床概念验证达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58ca9809c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

主要终点

2020-05-29

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

辉瑞疫苗Prevenar13用于老年患者研究达主要终点

2015-02-07

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

进仿制版3期临床达到主要终点，阿达木单抗霸主地位受到威胁？

2015-03-11

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

MSD骨质疏松症药物Odanacatib达3期试验主要终点

2015-08-11

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

辉瑞CDK4/6抑制剂palbociclib II期达主要终点

2014-09-22

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

GSK单抗药Arzerra III期CLL研究未达主要终点

2014-10-23

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

阿斯利康2种治疗自身免疫性疾病的单抗药物II期研究均达主要终点

2014-07-02

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

安斯泰来前列腺癌新药Xtandi III期PREVAIL达主要终点

2014-01-19

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

辉瑞戒烟药varenicline新研究达主要终点

2014-10-11

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

辉瑞潜在重磅药物tofacitinib 2个III期研究达主要终点

2014-02-18

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

ECC 2013辩论场：PFS是有效的主要终点吗？

2013-11-20

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Isis制药反义药物Isis-CRP Rx II期RA研究未达主要终点

2013-08-30

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

诺华抗癌药LDE225关键性BOLT研究达主要终点

2014-03-23

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Pacira制药Exparel III期肋间神经阻滞试验未达主要终点

2014-02-26

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

GSK冠心病药物darapladibIII期研究未达主要终点

2014-09-19

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

赛诺菲新胰岛素U300 4个III期研究达主要终点

2014-06-19

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

拜耳Eylea 2个III期糖尿病性黄斑水肿试验均达主要终点

2014-07-23

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

骨关节炎镇痛药物ARRY-797的临床概念验证达到主要终点

2013-05-10

科室
- - 订阅+
  - 更多科室
工具
服务